Search for:
  • Sign in
  • Register
  • Country Reports
  • Interviews
  • InFocus
  • Europe
  • Asia-Pacific
  • Americas
  • Middle East & Africa
  • Legal & Regulatory
  • Facts & Figures
  • Library
  • Op-eds
  • Shop
Monday, June 9, 2025
PharmaBoardroom
Sign In Register
  • Home
  • Country Reports
    • All
    • Americas
    • Asia-Pacific
    • Europe
    • Middle East & Africa
  • Exclusive interviews
    • All
    • Latest
    • Americas
    • Asia-Pacific
    • Europe
    • Middle East & Africa
  • Articles
    • All
    • Global
    • Latest
  • Legal & Regulatory
    • All
    • The Pharma Legal Handbook
    • Regulatory, Pricing and Reimbursement
    • Marketing, Manufacturing, Packaging and Labeling
    • Preclinical and Clinical Trials
  • Op-Eds & Contributions
  • InFigures
    • All
    • Rankings
    • Americas
    • Asia-Pacific
    • Europe
    • Middle East & Africa
  • Library
    • All
    • InFocus
    • InFigures
    • White Papers
  • Media Kit
  • Register
  • About Us
  • Country Reports
  • Interviews
  • InFocus
  • Europe
  • Asia-Pacific
  • Americas
  • Middle East & Africa
  • Legal & Regulatory
  • Facts & Figures
  • Library
  • Op-eds
  • Shop
France Pharma Report March 2019 Download

France,

March 2019

France – under the business-minded administration of President Emmanuel Macron – has been rapidly climbing investor priority rankings in recent years.

 

This report examines the potential impact of a swathe of ambitious recently-approved reforms and a new mood of optimism sweeping the country. These stand to impact the entire strategic direction of the French industry by taking private sector concerns much more into account, revitalizing the country’s industrial manufacturing base, boosting the growth prospects of its SMEs and repositioning France as an “innovation nation.”

 

This report features the exclusive comments of key stakeholders across the French healthcare value chain, including the global heads of French heavyweights Ipsen and Sanofi Pasteur, as well as government ministers, regulators, heads of pharma MNC affiliates, and representatives from the medtech and biotech industries.

France – under the business-minded administration of President Emmanuel Macron – has been rapidly climbing investor priority rankings in recent years.

 

This report examines the potential impact of a swathe of ambitious recently-approved reforms and a new mood of optimism sweeping the country. These stand to impact the entire strategic direction of the French industry by taking private sector concerns much more into account, revitalizing the country’s industrial manufacturing base, boosting the growth prospects of its SMEs and repositioning France as an “innovation nation.”

 

This report features the exclusive comments of key stakeholders across the French healthcare value chain, including the global heads of French heavyweights Ipsen and Sanofi Pasteur, as well as government ministers, regulators, heads of pharma MNC affiliates, and representatives from the medtech and biotech industries.

See more

Legal & Regulatory

report
Buy
Tags:
France, Pharma, Report
Share on Facebook Share on WhatsApp Share on Twitter Share on Linkedin Share in Email
Back
PharmaBoardroom

PharmaBoardroom Limited
Evolution House
Iceni Court, Delft Way,
Norwich, NR6 6BB UK

Latest

  • Articles
  • In Conversation
  • Facts & Figures
  • Country Reports
  • Legal & Regulatory
  • InFocus

More

  • About Us

Join Us

  • Email Newsletters
  • LinkedIn

Contact

+44 2078673717

info@stage.pharma.kalyna.dev

Legal & Privacy

  • Terms and Conditions
  • Privacy and Cookies policy
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here

logo

Sign in

Forgot password? Register Now